Both are radiofrequency microneedling. The clearest difference between them is what the FDA paperwork actually says. Virtue RF's clearance (K211562, 23 November 2021) names a cosmetic use: its Smart RF handpiece at 1 MHz is cleared for "the percutaneous treatment of facial wrinkles." Morpheus8's clearances name no cosmetic use at all — they cover electrocoagulation and hemostasis — surgical language for sealing tissue and stopping bleeding — and since 2023 coagulation or contraction of soft tissue.
That is a difference in what was reviewed, not proof that one works better. A 510(k) clearance means a device was judged substantially equivalent to an earlier device. Neither clearance is a finding of benefit, and Virtue RF's wrinkle indication applies to one handpiece at one frequency, not to the whole machine.
The second real difference is hardware breadth. Virtue RF's clearance documents three handpieces — two bipolar and one monopolar — across three frequencies. Morpheus8 is bipolar at a single frequency, with a family of tips that go deeper than most competitors.
The third is evidence, and here neither brand comes out well. No Virtue RF–specific published trial could be located. Morpheus8 has 16 PubMed records and no randomised controlled trial. Both are sold on a literature generated mostly by other machines.
Smart RF and Deep RF are bipolar; Exact RF is a monopolar single-needle handpiece. Needle arrays come as single, 12-needle or 36-needle.
Tips of 12, 24 and 40 pins plus a fixed-depth T tip, run on InMode's RF consoles.
The monopolar Exact RF handpiece is a single-needle design; its clearance cites Agnes as a reference device.
Pins are insulated except the distal 0.5 mm, per InMode's operator manual, so energy is released in the dermis rather than at the entry point.
The retrievable K211562 summary does not give a needle depth range. Any depth figure you are quoted for Virtue RF comes from the manufacturer or the clinic, not the clearance.
InMode's own manual gives 1–4 mm (Prime), 1–7 mm (standard) and 2–7 mm (Body).
No Virtue RF–specific published trial was located, so the brand rests on the general RF microneedling literature.
The best-evidenced use of the device class as a whole is atrophic acne scars.
No Fitzpatrick skin type limit is stated. The Deep RF and Exact RF handpieces carry no wrinkle claim.
Above 62 mJ/pin, on-label use is limited to skin types I–IV.
Virtue RF's cleared text reads, in full for the relevant part: "The Virtue RF System is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. Smart RF Handpiece: The Smart RF Handpiece with 1 MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles."
Read it carefully and three things follow. The wrinkle claim belongs to one handpiece, at one frequency, and no skin type limit is attached. Morpheus8's clearances contain no cosmetic wording at all, but do carry a real safety limit: above 62 mJ/pin the applicator is restricted on-label to skin types I to IV.
Virtue RF is not unusual in carrying a cosmetic indication, and Morpheus8 is not unusual in lacking one. A handful of devices in this class do have one in their cleared text — Vivace for facial wrinkles at 1 MHz in Fitzpatrick I–V, Profound Matrix for facial wrinkles in Fitzpatrick I–IV, and the Profound System for facial wrinkles and, with its SubQ handpiece, for the appearance of cellulite in Fitzpatrick I–III. Most of the rest — Potenza, Secret RF, Genius, Sylfirm X, Scarlet, Agnes, PiXel8-RF — carry generic electrosurgical wording, as Morpheus8 does.
Neither brand has much of its own. No published trial naming Virtue RF was located. Morpheus8 returns 16 PubMed records, none of them a randomised controlled trial, and several sitting in industry-sponsored journal supplements written by paid consultants.
What does exist is a body of work on the class, run on other machines. The most useful single map of it is Tan and colleagues' 2021 critical review of 42 higher-quality studies (PMID 33577211): 14 on skin rejuvenation, 7 on acne scars, 6 on acne, 5 on stretch marks, 5 on hyperhidrosis, 2 on melasma, and one each on rosacea, cellulite and hair loss. The strongest indication is atrophic acne scars — in a 2026 evaluator-blinded split-face trial (PMID 42312398, 30 completers) radiofrequency microneedling matched fractional CO2 laser, with shorter redness and fewer pigmentation events.
None of that was generated on either of these two devices.
A 2026 analysis of the FDA's MAUDE adverse-event database covering January 2013 to October 2025 (PMID 41886649) found 114 reports containing 224 events across radiofrequency microneedling devices. Textural changes made up 25.0% of events, pigmentary alteration 18.3%, fat loss 11.6%, inflammatory reactions 8.0%, burns 6.3% and pain 5.4%.
These are proportions of reported events, not a per-patient risk. MAUDE is voluntary and has no denominator, so it cannot tell you how often anything happens. It can tell you which problems occur. Fat loss is the one that marketing does not mention — and there is countervailing evidence too: Wu and colleagues (2024, PMID 38051121) measured the submental fat layer by ultrasound in 30 completers and found no significant change.
Tell your provider at booking if you get cold sores. Antiviral medication is started in advance, not after a blister appears. There is no published data on cold-sore reactivation after RF microneedling specifically; the practice is carried over from laser resurfacing, where it is well documented.